Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spahn, J. D.
Right arrow Articles by Kamada, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spahn, J. D.
Right arrow Articles by Kamada, A. K.

Special Considerations in the Use of Glucocorticoids in Children

Joseph D. Spahn MD1
Alan K. Kamada PharmD2
1 Divisions of Clinical Pharmacology and Allergy Immunology, Department of Pediatrics
2 Division of Clinical Pharmacology, National Jewish Center for Immunology and Respiratory Medicine, Denver, CO.

GCs are used commonly for the treatment of various inflammatory and autoimmune diseases. Although potent and generally effective, they are not without risks for producing serious adverse effects, especially when used in high doses for prolonged periods of time. Thus, the clinician must balance the therapeutic effects of GCs with their risks for adverse effects; using the lowest possible effective GC doses as well as maximizing other therapeutic modalities are means by which this goal can be achieved. Early recognition and appropriate management are other methods to minimize GC-induced adverse effects. Maximization of therapy, early recognition, and appropriate management of adverse effects can minimize the potential severe complications of GC therapy.




This article has been cited by other articles:


Home page
Arch DermatolHome page
M. E. George, V. Sharma, J. Jacobson, S. Simon, and A. J. Nopper
Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas
Arch Dermatol, August 1, 2004; 140(8): 963 - 969.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
A. Bereket and T. Erdogan
Oral Bisphosphonate Therapy for Vitamin D Intoxication of the Infant
Pediatrics, April 1, 2003; 111(4): 899 - 901.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
R. M STANBURY and E. M GRAHAM
Systemic corticosteroid therapy---side effects and their management
Br. J. Ophthalmol., June 1, 1998; 82(6): 704 - 708.
[Full Text]




HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 1995 by the American Academy of Pediatrics.